PVI
PYXS icon

Pura Vida Investments’s Pyxis Oncology PYXS Stock Holding History

Pura Vida Investments’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-113,362
Closed -$458K – 261
2022
Q1 		$458K Buy
113,362
+600
+0.5% +$4.39K 0.01% 205
2021
Q4 		$1.24M Buy
+112,762
New +$1.29M 0.04% 167

Other funds holding PYXS

LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Pura Vida Investments's PYXS Position: Q2 2022 in Review

Pura Vida Investments sold out of Pyxis Oncology (PYXS) in Q2 2022, closing a stake of 113,362 shares — an estimated $458K sold.

Pura Vida Investments first reported a position in PYXS in Q4 2021 and held it in 2 quarters. The position peaked at $1.24M in Q4 2021. 39 funds tracked by Wall St. Rank hold PYXS as of Q2 2022.

  • Pura Vida Investments reported no remaining Pyxis Oncology position as of Q2 2022 after selling out during the quarter.
  • Pura Vida Investments sold 113,362 Pyxis Oncology shares in Q2 2022, an estimated $458K.
  • Pura Vida Investments first reported a position in Pyxis Oncology in Q4 2021 and held it in 2 quarters.
  • Pura Vida Investments's Pyxis Oncology position peaked at $1.24M in Q4 2021.
  • 39 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2022.

Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.